Chimera Biotec joins the EU funded Edar project to adapt the Imperacer platform technology for the detection of novel biomarkers for the diagnosis of Alzheimer's disease
The consortium wants to find out whether the new markers can be used to test efficacy of new drugs, thereby contributing to new strategies for the diagnosis and treatment of Alzheimer's disease.
The European Commission has supported the study with euro620,000.
It is a collaborative project including 11 centres from six European countries and is coordinated by the VU University Medical Centre in Amsterdam, Netherlands.
Abnormalities in the processing of the beta amyloid protein are an important characteristic of Alzheimer's disease.
Moreover, recent studies have shown that beta amyloid precursor oligomers play an important role in the early stage of Alzheimer's disease.
"To describe and characterise these oligomers will be one of the most important advancements in the understanding of Alzheimer's disease in the next years" summarises Jan Detmers, Chimera Biotec's business development director.
Currently, many companies develop drugs that influence the processing of the beta amyloid peptide and its precursors.
In this study, it will be investigated whether the oligomers can be used as a diagnostic marker of Alzheimer's disease and whether it can be used to measure the effect of drug treatments.
Within this project Chimera Biotec aims to overcome the challenges in analytic performance by applying its innovative high sensitive Imperacer platform technology.
The Imperacer technology combines the advantages of flexible and robust protein detection through Elisa with the exponential signal amplification typical for PCR.
Imperacer uses antibody-DNA conjugates as a substitute for the antibody-enzyme conjugate used in Elisa.
Amplifying the conjugated marker-DNA typically results in a 100-10,000-fold increase in sensitivity over conventional Elisa.
